Member Info for Laura2022

Valirx CEO Dr Mark Eccleston for an interactive presentation and Q&A session on Monday, 21st October 2024 at 1pm where he will outline his vision and future direction for the Company

Https://www.londonstockexchange.com/news-article/OBD/commercial-update-for-fy24/16712053

The management team remains wholly confident in the inherent value of the Company's test products and its EpiSwitch platform and therefore, as part of these plans, directors, PDMRs and certain other senior staff have agreed to take 25% of their net pay in newly issued shares for the foreseeable future. Chief Executive Officer, Dr Jon Burrows will take 35% of his net pay in newly issued shares.

Notwithstanding the measures being taken to reduce the cost base, the Company will require additional cash resources by early Q1 of 2025. The Board has therefore launched a comprehensive review of the strategic options open to the Company. In addition to exploring available funding options, the review will consider a range of potential actions, including but not limited to a licensing or sale of Company assets - such as the EpiSwitch NST and EpiSwitch SCB tests - and a possible hive-off of the Company's US business into a separately funded entity. Currently, the strategic review does not envisage an offer for the Company under the City Code of Takeovers and Mergers. A further announcement regarding the outcome of the review will be provided in due course.

That's them nearly done

received notification on 11 October 2024 from New Technology Capital Group, LLC ("New Tech"), that New Tech's voting rights over the Company's ordinary shares are between 5% and 6% of the Company's total issued share capit

Although to be fair they'd already had 3 in 2 yrs one of which was the toxic warrant spiral that took SAR from £1.00 to 20p and even this one was 45% discount

However SAR now funded for the next part of their journey which hopefully re establishes the Pyc/SAR relationship

I'm trying to work out how you go from £0.2mln revenues to £20mln

X 100

Evening porky

You've accused me of being 4 different people and yet again apply one set.of rules for shares you're in to ones you're not

Hi PM

I am very interested in the valuations given by porky particularly given his previous comments on other shares

So , i ask my question again

Do you hold ?

Why don't you just sell .?

Jonathan Marren, Chief Executive Officer at Invinity said:

"We are delighted to see the announcement this morning from DESNZ. This is a very important step forward in paving the way for LDES technologies to make a large and meaningful impact on our national grid and confirms the Company's optimistic view on future policy support for Invinity's products in the UK market.

We look forward to continuing our regular engagement with DESNZ as well as Ofgem and other key stakeholders as the scheme moves through the remaining steps of the process. The support for LDES embodied in this scheme is most welcome and we look forward to our products playing an even greater role in supporting energy security, faster decarbonisation and lower costs for consumers in the UK.

Particularly as PYC announced their branch out into dermatology

Through this additional development work, Sareum intends to position SDC-1801 as a best-in-class TYK2/JAK1 inhibitor for autoimmune diseases, with an initial focus on psoriasis-a condition affecting over 60 million adults worldwide, representing a market opportunity exceeding US$30 billion.

PYC previously worked with SAR so now SAR announced their fund raise on Friday i wonder if they'll use PYC again

funding, alongside a A$ 1.9 million (c. £1 million) tax credit received on 8th October 2024, from Australia for running the Phase 1 clinical development of the Company's lead candidate SDC-1801, will enable the Company to conduct further development of SDC-1801, including longer-term toxicology studies, to prepare the asset for Phase 2 clinical trials thereby enhancing its potential value.

Thanks Porky

What Do you think the H2 figures will be ( and therfore the full years) , these H1 figures have since been superceded by the various regulator approvals in May-June

FINANCIAL HIGHLIGHTS

· Revenue and other income of £0.24m (H1 2022/3: £0.02m)

· R&D spend of £1.9m (H1 2022/3: £2.0m)

· Operating loss of £2.4m (H1 2022/3: £2.7m)

I think these numbers will be beaten when full year results are announced soon for year ended june 2024

Audited Final Results

 

genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces its audited Final Results for the year ended 30 June 2023.

 

Financial Highlights

· Loss for the year of £5.2m (2022: loss of £4.7m)

· R&D spend of £3.9m (2022: £3.9m)

· Cash at bank of £2.6m (2022: £4.6m)

Yes thanks Porky9

I think theor cash is fine Into 2025 even with cash burn of £300k ish a month , ( i made this point to Roger in summer when he falsely claimed GDR needed cash again )

Current revenues are about £1mln for GDR ?

However

As Kimg H says , if our dosing app with DosemeRx can cut costs on the Docetaxel drug which currently has sales of $3bln the surely the tool alone should be worth ££mlns to PYC going fowrd

Also , with PYC likely to hit £600k+ for H1 ( still time to land more contracts before Dec 2024) and with new biostatistics offering then I don't think £10mln valuation for PYC (comapred to current £1.4mln) is too adventurous

Found this post on another medi tech company forum

Valuing a meditech company often involves using revenue multiples, which can vary based on several factors such as the company's growth stage, market conditions, and specific sector within meditech. Here are some general guidelines:

1. Early-Stage Companies: Typically valued at lower multiples, around 4.5x to 5.5x revenuehttps://sharpsheets.io/blog/healthtech-startup-valuation-multiples/https://www.healthcare.digital/single-post/healthtech-m-a-multiples-current-trends-and-variables-driving-valuations.

2. Mid-Sized Companies: These might see multiples ranging from 5.0x to 7.0x https://www.healthcare.digital/single-post/healthtech-m-a-multiples-current-trends-and-variables-driving-valuations.

3. Large Companies: More established companies can have multiples from 7.0x to 9.0x or higherhttps://www.healthcare.digital/single-post/healthtech-m-a-multiples-current-trends-and-variables-driving-valuations.

Specific sectors within meditech also have different average multiples:

• Telehealth Companies: Around 5.5x revenuehttps://www.healthcare.digital/single-post/healthtech-m-a-multiples-current-trends-and-variables-driving-valuations.

• Medical Device Companies: Approximately 5.0x revenuehttps://www.healthcare.digital/single-post/healthtech-m-a-multiples-current-trends-and-variables-driving-valuations.

• Healthcare IT Companies: About 3.5x revenuehttps://www.healthcare.digital/single-post/healthtech-m-a-multiples-current-trends-and-variables-driving-valuations.

These multiples reflect the high growth potential and innovation within the meditech industry."

Hi porky

I'm looking at an investment here having previously been in for a trade

Can you please break down from current revenues and 2p25 projections how you think it can get to 50p/£200mln cap

Thanks

And interims go on to say

The Company has received interest from two Global Tier-1 OEMs to co-fund and adopt an ASIC solution from Ethernity. Should they choose to proceed this could lead to a significant increase in NRE payments to the Company in 2025-2026. Management believes that there is an addressable market that could enable the Company to achieve significant revenue growth over the coming years and aspire for the Company to reach annual revenues exceeding $35 million in five years.

These orders ARE mentioned in the interims Skid

Furthermore, over the past several months, the Company has been engaged in discussions with two Tier-1 wireless backhaul solutions providers. They both have prior experience with the Company's technology, and one has been successfully testing Ethernity's solution for the past nine months. Whilst no contracts have been secured to date, these vendors have expressed an interest in Ethernity's evolving FPGA technology and solution to an ASIC, as they believe that it would enable them to gain market share while simultaneously improving their respective gross margins.